Deals Of The Week: Tire-Kicking Season Continues Full-Swing
Executive Summary
As Roche’s reported interest in buying rare-disease specialist Alexion faded, new suitors popped up for oncology specialist Onyx. Plus news on deals between Spectrum and Talon, Pfizer and Sequella, Medtronic and Amgen, and a new direction for Rexahn.
You may also be interested in...
Rexahn Adds Drug Conjugate Platform To Its Oncology Offerings
The Rockville, Md.-based biotech hopes to bring more value to shareholders through a slew of polymer-conjugated cancer drugs that it will add to its pipeline while it continues moving its three lead cancer compounds forward.
Spectrum Bets On Marqibo In NHL With Low-Priced Talon Acquisition
Spectrum gains an approved drug with the deal and aims for label expansion. Talon’s high-profile investors are counting on an increase in Spectrum share price and post-acquisition milestones to break even.
Deals Of The Week Wonders: Who Will Buy Onyx?
Oncology-focused pharmas and multiple myeloma players, as well as would-be MM competitors, top Wall Street’s list of possible Onyx buyers. A successful deal could aid the longstanding biotech rally that has retrenched in recent weeks.